Informations générales (source: ClinicalTrials.gov)
JAKINIB Study: " 'Observational', Multicentre Trial Collecting Prospective and On-going Clinical and Laboratory Data for Patients Treated With JAK Inhibitors for Inflammatory Rheumatism According to EMA." (MAJIK)
Observational [Patient Registry]
Societe Francaise de Rhumatologie (Voir sur ClinicalTrials)
octobre 2019
juin 2030
29 juin 2024
Janus kinase (JAK) inhibitors are a new class of molecules available to the therapeutic
arsenal for chronic inflammatory rheumatic diseases.The tolerance profile of this new
class needs to be better defined and its use in real life further established.
The French Society of Rheumatologists intends to coordinate a prospective national
registry study for this follow-up.
This registry will include at least 1500 Rheumatoid Arthritis (RA) and 150 patients with
psoriatic arthritis from the start of treatment with JAK inhibitor and then followed for
5 years.
This registry is a longitudinal, multicentre, observational registry study. The objective
of this national registry is to get a better understanding of the safety profiles of JAK
inhibitors and get knowledge of their use in daily practice in order to optimize this use
and potentially integrate JAK inhibitors into personalised medicine strategies.
This registry will generate efficacy data, especially therapeutic maintenance,
observation, allowing inter-registry comparisons with other biologic compounds in the
French population, and can be aggregated with other similar registries in other
countries.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| AP-HP - Hôpital Bichat | Philippe Dieude | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Cochin | Jerôme AVOUAC, MD | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital La Pitié-Salpêtrière | Beatrice Banneville | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Lariboisiere-Fernand Widal | Frederic Lieute | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Saint Antoine | Jeremie Sellam | Contact (sur clinicalTrials) | |||
| CDS ACCES VISION SAINT MANDE | Contact (sur clinicalTrials) | ||||
| IFSI AP-HP DU CH AMBROISE PARÉ | Ilaria Padovano | Contact (sur clinicalTrials) | |||
| IFSI AVICENNE (AP-HP) | Luca Semerano | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CH de Douai - Douai - France | Audrey Juillard | Contact (sur clinicalTrials) | |||
| CH Mont de Marsan - Mont-de-Marsan - France | Marion Mirabel | Contact (sur clinicalTrials) | |||
| CH Saint Philibert - Lomme - France | Eric Houvenagel | Contact (sur clinicalTrials) | |||
| CH Troyes - Troyes - France | Kraoua Faten | Contact (sur clinicalTrials) | |||
| CH Valenciennes - Valenciennes - France | Xavier Deprez | Contact (sur clinicalTrials) | |||
| CHD de Vendee - La Roche-sur-Yon - France | Gregoire Cormier | Contact (sur clinicalTrials) | |||
| CHG Jacques Monod - Le Havre - France | Charles Zarnitski | Contact (sur clinicalTrials) | |||
| CHU Clermont Ferrand - Clermont-Ferrand - France | Anne Tournadre | Contact (sur clinicalTrials) | |||
| CHU de Besançon - Besançon - France | Clément PRATI, MD | Contact (sur clinicalTrials) | |||
| CHU de la Reunion - Saint-Denis - France | Xavier Guillot | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP Bicetre - Le Kremlin-Bicêtre - France | Raphaele Seror | Contact (sur clinicalTrials) | |||
| AP-HP Henri Mondor - Créteil - France | Pascal Claudepierre | Contact (sur clinicalTrials) | |||
| CH Antibes - Antibes - France | Lauren Natella | Contact (sur clinicalTrials) | |||
| CH Bourg-en-Bresse - Bourg-en-Bresse - France | Sylvie Roux | Contact (sur clinicalTrials) | |||
| CH Cannes - Cannes - France | Christine Albert | Contact (sur clinicalTrials) | |||
| CH Chartres - Chartres - France | Richard Damade | Contact (sur clinicalTrials) | |||
| CH Cholet - Cholet - France | Charles Leske | Contact (sur clinicalTrials) | |||
| CH Colombes - Colombes - France | Contact (sur clinicalTrials) | ||||
| CH Dax - Dax - France | Emilie Shipley | Contact (sur clinicalTrials) | |||
| CH de Dijon - Dijon - France | Andre Ramon | Contact (sur clinicalTrials) | |||
| CH Franche Comte - Belfort - France | Anne Lohse | Contact (sur clinicalTrials) | |||
| CH La Rochelle - La Rochelle - France | Bruno Gombert | Contact (sur clinicalTrials) | |||
| CH Le Mans - Le Mans - France | Emmanuelle Dernis | Contact (sur clinicalTrials) | |||
| CH Morlaix - Morlaix - France | Catherine Le Henaff | Contact (sur clinicalTrials) | |||
| CH Nevers - Nevers - France | Sylvie Melac-Ducamp | Contact (sur clinicalTrials) | |||
| CH Niort - Niort - France | Christian Lormeau | Contact (sur clinicalTrials) | |||
| CH Orleans - Orléans - France | Carine Salliot | Contact (sur clinicalTrials) | |||
| CH Pau - Pau - France | Vincent Germain | Contact (sur clinicalTrials) | |||
| CH Saint Nazaire - Saint-Nazaire - France | Contact (sur clinicalTrials) | ||||
| CH Valence - Valence - France | Contact (sur clinicalTrials) | ||||
| CHRU Brest - Brest - France | Divi Cornec | Contact (sur clinicalTrials) | |||
| CHU Caen - Caen - France | Anne-Christine Rat | Contact (sur clinicalTrials) | |||
| CHU de Bordeaux - Bordeaux - France | Marie-Elise TRUCHETET, MD | Contact (sur clinicalTrials) | |||
| CHU de Montpellier - Montpellier - France | Claire Daien | Contact (sur clinicalTrials) | |||
| CHU Lille - Lille - France | Rene-Marc Flipo | Contact (sur clinicalTrials) | |||
| CHU Lyon - Lyon - France | Fabienne Coury | Contact (sur clinicalTrials) | |||
| CHU Marseille Sainte-Marguerite - Marseille - France | Contact (sur clinicalTrials) | ||||
| CHU Nantes - Nantes - France | Benoit Le Goff | Contact (sur clinicalTrials) | |||
| CHU Nice - Nice - France | Christian Roux | Contact (sur clinicalTrials) | |||
| CHU Reims - Reims - France | Jean-Hugues Salmon | Contact (sur clinicalTrials) | |||
| CHU Rouen - Rouen - France | Contact (sur clinicalTrials) | ||||
| CHU Saint Etienne - Saint-Étienne - France | Thierry Thomas | Contact (sur clinicalTrials) | |||
| CHU Strasbourg - Strasbourg - France | Jacques-Eric Gottenberg | Contact (sur clinicalTrials) | |||
| CHU Toulouse - Toulouse - France | Adeline Ruyssen-Witrand | Contact (sur clinicalTrials) | |||
| CHU Tours - Tours - France | Philippe Goupille | Contact (sur clinicalTrials) | |||
| GH de Mulhouse - Mulhouse - France | Marie Desmurs | Contact (sur clinicalTrials) | |||
| Hopital La Croix Saint Simon - Paris - France | Pascal Chazerain | Contact (sur clinicalTrials) | |||
| Hôpital Saint Joseph - Marseille - France | Denis ARNIAUD | Contact (sur clinicalTrials) | |||
| Infirmerie protestante de Lyon - Lyon - France | Andre Basch | Contact (sur clinicalTrials) | |||
| Polyclinique Vauban - Valenciennes - France | Guy Baudens | Contact (sur clinicalTrials) | |||
| Private office - Bayonne - France | Christophe Bologna | Contact (sur clinicalTrials) | |||
| Private office - Limoges - France | Isabelle Chassaing | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion criteria
- Patients older than 18
- Patient treated with a JAK inhibitor in accordance with EMA, for chronic
inflammatory rheumatisms, independent of the therapeutic line
- Subject who is a member of a social security regime
- Free, declared, written consent signed by the subject and the investigator on the
day of inclusion Exclusion criteria
- Patient who cannot understand the implications and rules of the study
- Patient opposition to participating in the study
- Patients older than 18
- Patient treated with a JAK inhibitor in accordance with EMA, for chronic
inflammatory rheumatisms, independent of the therapeutic line
- Subject who is a member of a social security regime
- Free, declared, written consent signed by the subject and the investigator on the
day of inclusion Exclusion criteria
- Patient who cannot understand the implications and rules of the study
- Patient opposition to participating in the study